ABM
ABM Industries Incorporated
ABM offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
CAT
Caterpillar Inc.
CAT has the edge over ABM overall, supported by stronger modeled upside and stronger fundamentals.
ABM Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Under pressure |
ABM's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is under pressure.
CAT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
CAT's revenue, profitability, cash flow and balance sheet are all currently healthy.
ABM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 13x | $36.42 | -34% |
| Forward | 13x | $54.77 | — |
| Fair | 18x | $49.06 | -10% |
| Current | 20x | $54.77 | — |
| Expensive | 26x | $72.83 | +33% |
Historical ranges are pointers, not guarantees.
ABM has the edge over CAT in the historical PE scenario, which offers more potential upside but is not a forecast.
CAT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $380 | -37% |
| Fair | 18x | $461 | -24% |
| Forward | 20x | $605 | — |
| Current | 24x | $605 | — |
| Expensive | 33x | $840 | +39% |
Historical ranges are pointers, not guarantees.
CAT's PE is in its expensive range at 24x. If earnings grow as analysts expect, today's price would be 20x next year's earnings, in its fair range.
ABM Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Stable | |
| Limited | |
| High |
Analysts expect ABM's earnings to grow, with its revenue and profitability holding steady.
CAT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Low |
CAT has the edge over ABM on the outlook, with more favorable revenue and profitability expectations.
ABM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.36 | +57% |
| Q3 2026 | $2.77 | +50% |
| Q2 2026 | $2.60 | +108% |
| Q1 2026 | $2.54 | +100% |
| Q4 2025 | $2.59 | +102% |
| Q3 2025 | $1.85 | -24% |
| Q2 2025 | $1.25 | -67% |
| Q1 2025 | $1.27 | -68% |
| Q4 2024 | $1.28 | -66% |
ABM has the edge over CAT on earnings, with more consistent year-over-year improvement.
CAT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $29.73 | +17% |
| Q3 2026 | $25.48 | +31% |
| Q2 2026 | $23.23 | +18% |
| Q1 2026 | $20.08 | -2% |
| Q4 2025 | $18.81 | -15% |
| Q3 2025 | $19.46 | -9.7% |
| Q2 2025 | $19.64 | -10% |
| Q1 2025 | $20.50 | -7.4% |
| Q4 2024 | $22.05 | +9.6% |
CAT earned $25.48 per share over the past year, up 31% from the year before.
ABM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.3B | +4.2% |
| Q2 2026 | $2.3B | +8.4% |
| Q1 2026 | $2.2B | +6.1% |
| Q4 2025 | $2.3B | +5.4% |
| Q3 2025 | $2.2B | +6.2% |
| Q2 2025 | $2.1B | +4.6% |
| Q1 2025 | $2.1B | +2.2% |
| Q4 2024 | $2.2B | +4% |
ABM's revenue has grown year over year for 22 quarters in a row: $2.3B last quarter, up 4.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 4% | +0.2 points |
| Q2 2026 | 3.8% | -0.1 points |
| Q1 2026 | 3.3% | -0.3 points |
| Q4 2025 | 3% | +2.1 points |
| Q3 2025 | 3.8% | +2 points |
| Q2 2025 | 3.9% | -0.1 points |
| Q1 2025 | 3.7% | +0.1 points |
| Q4 2024 | 0.9% | -4.2 points |
ABM's operating margin was 4% last quarter, about level with the same quarter a year ago.
CAT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.7B | +17% |
| Q2 2026 | $20.5B | +24% |
| Q1 2026 | $17.4B | +22% |
| Q4 2025 | $19.1B | +18% |
| Q3 2025 | $17.6B | +9.5% |
| Q2 2025 | $16.6B | -0.7% |
| Q1 2025 | $14.2B | -9.8% |
| Q4 2024 | $16.2B | -5% |
CAT's revenue has grown year over year for five quarters in a row: $20.7B last quarter, up 17% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +3.1 points |
| Q2 2026 | 21% | +3.6 points |
| Q1 2026 | 18% | -0.4 points |
| Q4 2025 | 14% | -4.1 points |
| Q3 2025 | 17% | -2.2 points |
| Q2 2025 | 17% | -3.6 points |
| Q1 2025 | 18% | -4.2 points |
| Q4 2024 | 18% | -0.3 points |
CAT has the edge over ABM on profitability, with a higher operating margin.
ABM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $128.4M | -14% |
| Q2 2026 | $22.4M | +47% |
| Q1 2026 | $48.8M | +$171.7M |
| Q4 2025 | $112.7M | +622% |
| Q3 2025 | $150.1M | +135% |
| Q2 2025 | $15.2M | -85% |
| Q1 2025 | -$122.9M | -$109.2M |
| Q4 2024 | $15.6M | -87% |
ABM still generates free cash flow, though less than at its 2020 peak: $312M over the past year.
CAT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +19% |
| Q2 2026 | $3.8B | +47% |
| Q1 2026 | $1.1B | +97% |
| Q4 2025 | $2.7B | +0.1% |
| Q3 2025 | $3.1B | -1.5% |
| Q2 2025 | $2.6B | -4.2% |
| Q1 2025 | $579M | -63% |
| Q4 2024 | $2.7B | -22% |
CAT generated $11.3B in free cash flow over the past year, up 26% from the year before.
ABM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +200K shares |
| 1 year | -5.6% | -3.5M shares |
| 3 years | -11% | -7.3M shares |
| 5 years | -12% | -8.2M shares |
| Available history | -11% | -7.6M shares |
ABM has the edge over CAT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $3M |
| Q1 2026 | $91.7M |
| Q4 2025 | $73.7M |
| Q3 2025 | $27.2M |
| Q2 2025 | — |
| Q1 2025 | $21.3M |
| Q4 2024 | $32.3M |
ABM spent $168M buying back its own shares over the past year, up 108% from the year before.
CAT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -1.6M shares |
| 1 year | -2.1% | -9.9M shares |
| 3 years | -10% | -51.7M shares |
| 5 years | -16% | -86.7M shares |
| Available history | -19% | -107M shares |
CAT has 461M diluted shares, down 2.1% from a year ago, with $8.1B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.2B |
| Q2 2026 | $1.5B |
| Q1 2026 | $5B |
| Q4 2025 | $340M |
| Q3 2025 | $362M |
| Q2 2025 | $828M |
| Q1 2025 | $3.7B |
| Q4 2024 | $640M |
CAT spent $8.1B buying back its own shares over the past year, up 47% from the year before.
ABM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.8x | Elevated |
| Q2 2026 | 4.2x | High |
| Q1 2026 | 3.7x | Elevated |
| Q4 2025 | 3.5x | Elevated |
| Q3 2025 | 4.0x | Elevated |
| Q2 2025 | 4.6x | High |
| Q1 2025 | 4.6x | High |
| Q4 2024 | 4.0x | Elevated |
ABM's net debt is about 3.8 years of its operating earnings (EBITDA), about the same as a year ago.
CAT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | 2.0x | Healthy |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | 1.6x | Healthy |
CAT has the edge over ABM on leverage, with a lower net debt burden relative to earnings.
ABM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 72.1 | Overbought |
| Stochastic | 82.4 | Overbought |
ABM's weekly RSI is 72 (overbought) and its Stochastic is 82 (overbought).
CAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.7 | Neutral |
| Stochastic | 6.7 | Oversold |
CAT's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
ABM PE vs Industrials Sector
| Metric | ABM | Sector median | Relative |
|---|---|---|---|
| PE | 20x | 24x | 18% below |
| PE % | 56 | 58 | 2 pts below |
ABM has the edge over CAT on valuation relative to its sector.
CAT PE vs Industrials Sector
| Metric | CAT | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 24x | 1.1% below |
| PE % | 69 | 58 | 11 pts above |
CAT is trading at 24x earnings, in line with the Industrials sector's median of 24x.
ABM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $51.8 | 5.8% above |
| 20 week MA | $49.2 | 11% above |
| 50 week MA | $45.2 | 21% above |
| 100 week MA | $46.7 | 17% above |
| 200 week MA | $46.5 | 18% above |
ABM has the edge over CAT on trend strength, trading above more of its moving averages.
CAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $709.0 | 15% below |
| 20 week MA | $797.0 | 24% below |
| 50 week MA | $771.3 | 22% below |
| 100 week MA | $586.7 | 3.2% above |
| 200 week MA | $443.1 | 37% above |
CAT has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 37% above its 200-week average.
ABM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $38.5 | $37.7 | -2.1% |
| 2021 | $37.7 | $41.5 | +10% |
| 2022 | $41.5 | $44.1 | +6.2% |
| 2023 | $44.1 | $44.8 | +1.6% |
| 2024 | $44.8 | $51.0 | +14% |
| 2025 | $51.0 | $42.7 | -16% |
| 2026 YTD | $42.7 | $54.8 | +28% |
ABM has the edge over CAT on returns for 2026, with the stronger performance.
CAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $148.3 | $179.6 | +21% |
| 2021 | $179.6 | $206.2 | +15% |
| 2022 | $206.2 | $239.9 | +16% |
| 2023 | $239.9 | $295.7 | +23% |
| 2024 | $295.7 | $364.9 | +23% |
| 2025 | $364.9 | $583.0 | +60% |
| 2026 YTD | $583.0 | $605.3 | +3.8% |
CAT has finished every year since 2020 higher, and it's up 3.8% so far in 2026.